Posted on 7/24/17
These 5 Drugs Could Be Worth $45 Billion -- and They're Not Even on the Market Yet
$45 billion for five experimental drugs.That's how much market research firm EvaluatePharma projects the five most valuable pipeline candidates are worth right now. The firm calculated . . .
Posted on 7/24/17
Better Buy: AbbVie Inc. vs. Johnson & Johnson
U.S.-based pharmaceutical companies are enjoying a much friendlier business environment under President Trump than his predecessor. President Trump, after all, has backed away from the repeated . . .
Posted on 7/24/17
Better Buy: Celgene Corporation vs. Gilead Sciences, Inc.
Celgene (NASDAQ:CELG) and Gilead Sciences (NASDAQ:GILD) are two big biotechs facing dramatically different outlooks for the future. Their stock prices reflect that reality. Celgene's share price . . .
Posted on 7/24/17
5 Things You Probably Didn't Know About Pfizer Inc.
Many people can name one of Pfizer's (NYSE:PFE) products. From over-the-counter products such as Advil and Robitussin to powerful prescription drugs such as Eliquis and Ibrance, . . .
Posted on 7/24/17
Brainstorm Awarded $16 Million Non-Dilutive Grant from CIRM
Brainstorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leading developer of adult stem cell technologies for neurodegenerative diseases, today announced that the California Institute for Regenerative Medicine . . .
Posted on 7/21/17
Cyclacel Closes $15.2M Underwritten Public Offering and Full Exercise of Over-Allotment Option
BERKELEY HEIGHTS, N.J., July 21, 2017 (GLOBE NEWSWIRE) -- Cyclacel Pharmaceuticals, Inc. (NASDAQ:CYCC), a clinical-stage biopharmaceutical company using cell cycle, transcriptional regulation and DNA damage response . . .
Posted on 7/20/17
MTBC Named in 2017 Ranking of the Top 15 Medical Billing Companies in the United States
MTBC (NASDAQ: MTBC) (NASDAQ: MTBCP), a leading provider of proprietary, cloud-based healthcare IT solutions and services, today announced that it has been ranked as one of . . .
Posted on 7/20/17
Novartis Will Hit $100 This Year
There are a lot of moving parts going on in Novartis AG (ADR)(NYSE:NVS) at present, but I still see strong growth coming down the track. The . . .
Posted on 7/20/17
5 Off-the-Radar Numbers to Take Note of in Johnson & Johnson's Second-Quarter Report
It's officially earnings season, which can only mean one thing: Johnson & Johnson(NYSE:JNJ) is kicking things off for big pharmaceutical companies.On Tuesday morning, July 18, Johnson . . .
Posted on 7/20/17
J&J: Some Good News, But Here's Why It's Dropped A Level Or Two
IntroductionJohnson & Johnson (JNJ) had an unimpressive quarter and guided down. Yet the stock moved up, participating in the strong global rally that equities are enjoying.I'd . . .
Posted on 7/20/17
Johnson & Johnson: This Market Will Buy Anything
Before the open on Tuesday, Johnson & Johnson (JNJ) reported Q2 earningsthat weren't very impressive. The stock though jumped 2% on the news sending the stock . . .
Posted on 7/20/17
Better Buy: Celldex Therapeutics, Inc. vs. Juno Therapeutics
Celldex Therapeutics (NASDAQ:CLDX) and Juno Therapeutics (NASDAQ:JUNO) are both once-promising clinical-stage biotechs that have fallen on extremely hard times of late. Over the past two and . . .
Posted on 7/20/17
Emergent BioSolutions To Acquire Raxibacumab From GSK
Emergent BioSolutions Inc. (NYSE:EBS) announced today that it has entered into an agreement with GSK (LSE/NYSE: GSK)
Posted on 7/20/17
Inovio Announces Pricing of Public Offering of Common Stock
PLYMOUTH MEETING, Pa., July 19, 2017 (GLOBE NEWSWIRE) -- Inovio Pharmaceuticals, Inc. (NASDAQ:INO) today announced the pricing of an underwritten public offering of 12,500,000 shares of . . .
Posted on 7/20/17
Henry Schein Launches New Medical Website
Henry Schein, Inc., (Nasdaq: HSIC) today unveiled a newly designed website for Henry Schein Medical (www.henryschein.com/medical), the company's medical division, and announced an improved e-commerce solution . . .
Posted on 7/19/17
Cyclacel Prices $13.2 Million Underwritten Public Offering
BERKELEY HEIGHTS, N.J., July 19, 2017 (GLOBE NEWSWIRE) -- Cyclacel Pharmaceuticals, Inc. (NASDAQ:CYCC), a clinical-stage biopharmaceutical company using cell cycle, transcriptional regulation and DNA damage response . . .
Posted on 7/19/17
Johnson & Johnson's (JNJ) CEO Alex Gorsky on Q2 2017 Results - Earnings Call Transcript
Johnson & Johnson (NYSE:JNJ)Q2 2017 Results Earnings Conference CallJuly 18, 2017, 08:30 AM ETExecutivesJoseph Wolk - VP, IRAlex Gorsky - Chairman & CEODominic Caruso - EVP . . .
Posted on 7/19/17
Despite Falling Drug Sales, Johnson & Johnson Remains Optimistic
Johnson & Johnson (NYSE:JNJ) owes much of its recent success to the strength of its pharmaceutical division. Even though the company also has extensive exposure to . . .
Posted on 7/24/17
Glenmark Pharmaceuticals Enters Exclusive Agreement with Cyndea Pharma S.L.
Glenmark Pharmaceuticals, a global pharmaceutical company, announced today it has entered into a development, license, manufacture and commercial supply agreement with Cyndea Pharma S.L., granting exclusive . . .
Posted on 7/19/17
New Jersey Plastic Surgery Center Raises Over $7,000 for Alzheimer's Research & Education
Alzheimer's disease affects 1 in 10 people over aged 65 in the U.S., causing progressive loss of memory and brain function. It can be devastating for . . .
Posted on 7/18/17
OncLive and Targeted Oncology Partner with the Association of Community Cancer Centers
CRANBURY, N.J.--(BUSINESS WIRE)--OncLive® and Targeted Oncology™ are proud to announce they’ve partnered with the Association of Community Cancer Centers (ACCC) as a part of its Strategic . . .
Posted on 7/18/17
Johnson & Johnson Is Delivering
Johnson & Johnson (NYSE:JNJ) has just reported earnings which once again continue to impress here in 2017 which I have described as a key year for . . .
Posted on 7/18/17
Johnson & Johnson's Tremfya: A Potential Blockbuster Drug
Last week, Johnson & Johnson (JNJ) got an approval for its interleukin (IL)-23 inhibitor Tremfya for the treatment of adult patients suffering from moderate to severe . . .
Posted on 7/18/17
Johnson & Johnson Reports 2017 Second-Quarter Results
Johnson & Johnson (NYSE: JNJ) today announced sales of $18.8 billion for the second quarter of 2017, an increase of 1.9% as compared to the second . . .
Posted on 7/18/17
BrainStorm Announces Agreements with Mass. General Hospital and California Pacific Medical Center to Participate in Phase 3 Trial of NurOwn in ALS
BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leading developer of adult stem cell technologies for neurodegenerative diseases, today announced that it has signed definitive agreements with . . .

